BiomX Inc. (NYSE American: PHGE) (together with its subsidiaries and/or associates, “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the closing of its previously announced (March 6, 2024) acquisition (the “Acquisition”) of Adaptive Phage Therapeutics, Inc. (“APT”), a U.S.-based privately-held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, and its previously announced $50 million private placement to certain institutional accredited investors, which was led by affiliates of Deerfield Management Company and the AMR Action Fund.
Read the full article: BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50M Financing //
Source: https://www.globenewswire.com/news-release/2024/03/18/2847627/0/en/BiomX-Announces-Closing-of-the-Acquisition-of-Adaptive-Phage-Therapeutics-and-Concurrent-50-Million-Financing.html